Investigating metabolic effect modulation by AD risk factors
We used CSF biomarkers, FDG-PET imaging, and serum metabolomics data on 139 metabolites to investigate metabolic effects in relation to sex and AD and their interaction. Of 1517 ADNI participants, 1082 had CSF Aβ1–42 and p-tau levels and 1143 had FDG-PET data available (Table 1). We included all individuals with respective data regardless of diagnostic classification, as we were interested in these three representatives of the A-T-N AD biomarker schema54,55 as our main readouts. In this data set, there was no significant difference in the number of APOE ε4+/− participants between females and males (PFisher’s exact > 0.3). Of the three AD biomarkers, only p-tau levels were significantly different between sexes in covariate-adjusted regression models (PREG = 0.01 after adjustment for three tests) with slightly…
